Seroatlas · Human Serome Atlas

GFOD2

Glucose-fructose oxidoreductase domain-containing protein 2

Also known as: FLJ23802, GFOD2_HUMAN, MGC11335

Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene

Protein identityUniProt · HPA

UniProt accession: Q3B7J2
Gene: GFOD2
Ensembl: ENSG00000141098
Chromosome: 16
Canonical length: 385 aa
Protein class: Predicted intracellular proteins, Predicted secreted proteins
Subcellular location: Nucleoplasm,Cytosol
Secretome location: Secreted to blood

OverviewNCBI Gene

Predicted to enable nucleotide binding activity and oxidoreductase activity. Predicted to be involved in extracellular matrix organization. Predicted to be located in extracellular region. Predicted to be active in extracellular matrix. [provided by Alliance of Genome Resources, Jul 2025]

Canonical amino-acid sequenceUniProt

385 residues, UniProt reviewed canonical sequence.

>Q3B7J2|GFOD2
     1  MKMLPGVGVF GTGSSARVLV PLLRAEGFTV EALWGKTEEE AKQLAEEMNI AFYTSRTDDI
    61  LLHQDVDLVC ISIPPPLTRQ ISVKALGIGK NVVCEKAATS VDAFRMVTAS RYYPQLMSLV
   121  GNVLRFLPAF VRMKQLISEH YVGAVMICDA RIYSGSLLSP SYGWICDELM GGGGLHTMGT
   181  YIVDLLTHLT GRRAEKVHGL LKTFVRQNAA IRGIRHVTSD DFCFFQMLMG GGVCSTVTLN
   241  FNMPGAFVHE VMVVGSAGRL VARGADLYGQ KNSATQEELL LRDSLAVGAG LPEQGPQDVP
   301  LLYLKGMVYM VQALRQSFQG QGDRRTWDRT PVSMAASFED GLYMQSVVDA IKRSSRSGEW
   361  EAVEVLTEEP DTNQNLCEAL QRNNL

LocalizationUniProt · AlphaFold · HPA

Whether an antibody against GFOD2 can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.

Antibody reachability: Secreted
Secreted: Yes
Transmembrane segments: 0
Mean surface accessibility (rSASA): 0.24
Highest tissue expression: 59 nTPM

Expression across tissuesHPA

Tissue

cerebellum: 59 nTPM
liver: 41 nTPM
esophagus: 34 nTPM
vagina: 26 nTPM
cervix: 23 nTPM
cerebral cortex: 21 nTPM

Single-cell type

esophageal apical cells: 430 nCPM
early spermatids: 112 nCPM
neutrophil progenitors: 105 nCPM
hepatocytes: 86 nCPM
suprabasal keratinocytes: 77 nCPM
lymphatic endothelial cells: 69 nCPM

Immune cell

T-reg: 9.2 nTPM
neutrophil: 9 nTPM
memory CD8 T-cell: 7.8 nTPM
memory CD4 T-cell: 7.7 nTPM
MAIT T-cell: 7.2 nTPM
naive B-cell: 7 nTPM

Brain region

cerebellum: 56 nTPM
hypothalamus: 29 nTPM
pons: 29 nTPM
cerebral cortex: 28 nTPM
choroid plexus: 28 nTPM
basal ganglia: 27 nTPM

Genetic constraint and essentialitygnomAD · DepMap

Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.

gnomAD LOEUF (loss-of-function intolerance): 0.82
gnomAD pLI: 0.05
gnomAD missense Z: 1.01
DepMap mean gene effect: -0.17
DepMap dependency class: selective

Cancer expressionTCGA

Across TCGA tumor cohorts, this protein is over-expressed in roughly 4% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).

OntologyGO

Biological processes

extracellular matrix organization

Molecular functions

Cellular components

extracellular matrix

Protein domainsUniProt · Pfam · InterPro

KeywordsUniProt

Antibody and autoantibody relevanceSeroatlas analysis

Seroatlas reads GFOD2 as an antibody target. Whether an autoantibody or antibody against GFOD2 could matter depends on whether native GFOD2 is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.

GFOD2 is annotated as secreted, so native GFOD2 circulates and is directly accessible to antibodies. Secreted and cell-surface proteins are the autoantibody targets most likely to act like drugs, blocking or depleting the native protein.

Annotation status

The present source text does not explicitly label GFOD2 as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.

Loading the interactive Seroatlas protein explorer...